Skip to main content
Drug Delivery logoLink to Drug Delivery
. 2022 Feb 25;29(1):664–678. doi: 10.1080/10717544.2022.2039804

Metal nanoparticles as a promising technology in targeted cancer treatment

Jia-Jie Xu a,b, Wan-Chen Zhang a,b,c, Ya-Wen Guo a,b, Xiao-Yi Chen d,, You-Ni Zhang e,
PMCID: PMC8890514  PMID: 35209786

Abstract

Traditional anticancer treatments have several limitations, but cancer is still one of the deadliest diseases. As a result, new anticancer drugs are required for the treatment of cancer. The use of metal nanoparticles (NPs) as alternative chemotherapeutic drugs is on the rise in cancer research. Metal NPs have the potential for use in a wide range of applications. Natural or surface-induced anticancer effects can be found in metals. The focus of this review is on the therapeutic potential of metal-based NPs. The potential of various types of metal NPs for tumor targeting will be discussed for cancer treatment. The in vivo application of metal NPs for solid tumors will be reviewed. Risk factors involved in the clinical application of metal NPs will also be summarized.

Keywords: Cancer treatment, metal nanoparticles, targeting, radiation therapy, hyperthermia

1. Introduction

Cancer is a condition in which abnormalities in the genome arise. These changes trigger unregulated cell division, resulting in tissue damage (Pugazhendhi et al., 2018). Cancer is a multifactorial disease because of its complex combination of hereditary and environmental components. DNA damage is the primary cause of the abnormalities responsible for cancer (Rivas-Domínguez et al., 2021). Cancer has the highest clinical, social, and economic burden of any human disease in terms of cause-specific disability-adjusted life years (DALYs). The overall risk of developing cancer for people aged 0–74 years is 20.2% (22.4% in men and 18.2% in women, respectively) (Mattiuzzi & Lippi, 2019). Sung et al. reported alarming global cancer statistics for the year 2020. Globally, an estimated 19.3 million new cancer cases (18.1 million excluding nonmelanoma skin cancer) and almost 10.0 million cancer deaths (9.9 million excluding nonmelanoma skin cancer) occurred in 2020. As the most diagnosed cancer, female breast cancer exceeded lung cancer. Breast cancer had 2.3 million new cases (11.7%), followed by lung (11.4%), colorectal (10.0%), prostate (7.3%), and stomach (5.6%) cancers. Lung cancer remained the leading cause of cancer death, with an estimated 1.8 million deaths (18%), followed by colorectal (9.4%), liver (8.3%), stomach (7.7%), and female breast (6.9%) cancers (Sung et al., 2021). According to a report by the World Health Organization (WHO), cancer was the primary cause of mortality worldwide, contributing to about 10 million deaths in 2020. A statistical overview of newly reported cancer cases and deaths reported are presented in Figure 1 (Cancer, 2022).

Figure 1.

Figure 1.

Statistics on the deaths due to cancer and newly reported cancer cases in the year 2020. MM: millions of people.

The most prevalent cancer therapies are chemotherapy, radiation, and surgery (Singhal et al., 2010). One of the most frequent cancer treatments is chemotherapy. Conventional chemotherapy mainly kills cancer cells by blocking mitosis and preventing DNA synthesis. Unintended and sometimes fatal side effects may occur when chemotherapeutic drugs target healthy tissues, particularly those that are rapidly expanding like blood and digestive tract cell membranes (Hossen et al., 2019). Traditional chemotherapy must be supplemented or replaced with less harmful systems due to the harm that conventional chemotherapeutic agents cause to healthy cells (Yan et al., 2020). Similarly, radiotherapy has many disadvantages as the radiations are also delivered to the healthy tissues surrounding the tumor and have the potential to harm them (Çeşmeli & Avci, 2019). Surgical therapy is not only costly but also a very complicated procedure. It requires specific expertise as well. Surgical therapy may also necessitate additional clinic visits due to suture removal, infection, contact dermatitis, spitting sutures, and graft check, among other things. Furthermore, many elderly patients require additional care after surgery, such as dressing changes, transportation, and follow-up visits, which adds to the cost of surgical therapy (Ahluwalia et al., 2020).

Nanotechnology has opened a new era in every field of life. The timeline of the advancement in nanotechnology has been represented in Figure 2. The ability of nanotechnology to detect a wide range of molecular signals and biomarkers in real-time is just what drives breakthroughs in early detection, diagnostics, prognostics, and therapeutic strategy. Cancer nanotherapeutics have overcome several shortcomings of conventional therapies, including nonspecific biodistribution, low water solubility, and poor bioavailability. It provides high sensitivity, specificity, and multiplexed measurement capacity (Zhang et al., 2019). A nanoparticle (NP) is a particle that has dimensions between 1 and 100 nm. When compared to the traditional drug delivery systems, NP-based drug delivery systems have higher efficacy due to increased half-life of vulnerable drugs and proteins, improved solubility of hydrophobic drugs, and the ability to control and target drug release in diseased sites (Dang & Guan, 2020). The types and characteristics of NPs based on size (1–100 nm), type (metal or polymeric), shape, and targeting are depicted in Figure 3.

Figure 2.

Figure 2.

Timeline of the advancement in nanotechnology.

Figure 3.

Figure 3.

NPs categorized based on their size, material, surface, and shape.

Metal NPs have gained specific attention among all the NPs because these have the potential to serve as multipurpose agents. Gold, silver, iron and/or iron oxide, zinc, titanium, cerium oxide, nickel, copper, magnesium, barium, calcium, and bismuth-based metal NPs have been reported as a cancer treatment. The leading role of metal NPs in the current research platforms against cancer, and the research interest in this topic is increasing day by day, as can be depicted in Figure 4. The comparison of five commonly synthesized metal NPs showed that gold NPs are among the leading, followed by silver and magnetic nanoparticles (MNPs). Several studies have shown metal NPs can be used to treat cancer and preliminary and clinical trials are now underway. The non-noble metal-based cancer therapy can progress toward cost-effective treatment as compared to expensive chemotherapy.

Figure 4.

Figure 4.

Number of publications for the year 2001–2021. Data retrieved from sciencedirect.com with search terms ‘metal’, or respective ‘metal name’, ‘nanoparticle’, and ‘cancer’ on January 22 2022.

In this review, the role of metal NPs in cancer therapy will be discussed. It will be examined how metal NPs reach the target areas by exploiting either the leaky vasculature within the tumor or targeting the overexpressed receptors on the tumor cells. The purpose of this article is to enlighten researchers, particularly those working on nanotechnology-based cancer therapy, about the potential of metal NPs in cancer treatment. The advantages of noble and non-noble metals and their drawbacks will be highlighted. The clinical potential of metal NPs will be determined by their efficacy against cancer cell lines and in vivo tumors. The last part will deliberate the toxicity concerns of the metal NPs in clinical application.

2. Mechanism of cancer-targeting

Metal NPs have been reported to have antitumor properties. The mechanisms of action involved in cancer therapeutics have been discussed below. Figure 5 illustrates these mechanisms.

Figure 5.

Figure 5.

Mechanisms involved in cancer targeting.

2.1. Active or passive targeting of tumor

Therapeutic agent accumulation can be enhanced by metal NP treatments in two ways: passive and active. For cancer treatment, abnormal branching and leaky sites with pore sizes ranging from 100 nm to several hundred nanometers are commonly found in tumor vasculatures. The reason is the rapid development of endothelial cells reduced the number of pericytes (Lok et al., 2014). Due to this leaky vasculature, the body concentrates inert metal NPs in the tumor under the passive targeting mechanism. This is referred to as the increased permeability and retention (EPR) effect. On the other hand, active targeting enhances the therapeutic delivery system by functionally modifying the metal NP's surface, resulting in selective tissue targeting (Pissuwan et al., 2006). The surface modification of NPs with tumor-targeting ligands such as antibodies, folic acid, and peptides, or the incorporation of tumor-targeting ligands into NPs via disulfide bonding, might result in targeted intra-tumor drug release (Wang et al., 2012). In a study, silver NPs functionalized with a fluorescent cyclic arginine–glycine–aspartic acid (RGD) peptide were found to be effective in identifying and targeting cancerous cells. Researchers found that the RGD peptide sequence can interact specifically with integrins, which are critical receptors for cancer growth and bacterial adhesion/invasion. Immobilization of a fluorescent RGD peptide onto silver NPs, with a diameter of 13 nm, was used to functionalize the hybrid peptide–metal NPs biointerface. Cellular uptake by SH-SY5Y neuroblastoma and K562 chronic myelogenous leukemia cells was confirmed by confocal microscope imaging (Di Pietro et al., 2016).

2.2. Tumor targeting through gene silencing

The regulation of gene expression in a cell to prohibit the expression of a specific gene is known as gene silencing. Due to its potential to suppress genes implicated in tumor formation, gene silencing grasps promising cancer therapy gene silencing is the process of altering gene expression on an epigenetic level. This is accomplished mostly through the use of antisense DNA and short interfering RNA (Liu et al., 2019). Fernandes & Baptista (2017) reported gene silencing using multifunctional gold NPs for cancer therapy to improve tumor cell identification and uptake. Gold NPs' surfaces were functionalized using targeting peptides. This approach inhibits KRAS gene expression in colorectal cancer cell lines while leaving healthy fibroblasts unharmed. Gene silencing with small interfering RNA (siRNA) is another option. siRNAs can be delivered to cells by using a platelet cell membrane-coated metal (zinc)-organic framework (MOF). Using a simple one-pot method, synthetic siRNAs were loaded onto porous metal-organic framework (MOF) NPs. pH affects the structural integrity of MOF scaffolds. In vitro targeting and intracellular localization were performed on human SK-BR-3 breast cancer cells (HTB-30; American Type Culture Collection, Manassas, VA). To bind specifically to cancer cells, a platelet membrane coating was employed (Fernandes & Baptista, 2017).

2.3. Drug delivery through nanoparticles

Cancer drugs in clinical practice are low molecular weight chemicals that can diffuse easily into healthy tissues as well as tumor tissues. This results in an even distribution throughout the body, a short half-life, and a rapid clearance rate. The amount of medicine that reaches the target site is very low, lowers therapeutic efficacy, and increases the risk of side effects, including the possibility of drug resistance (Skoetz et al., 2017; Farzin et al., 2020). Metal NPs can act as vectors for targeted drug delivery. Both hydrophobic drugs, e.g. paclitaxel loaded selenium NPs (Bidkar et al., 2017) and hydrophilic drugs, e.g. doxorubicin (DOX) loaded iron oxide (Fe3O4@SiO2@mSiO2) NP drug delivery system (Gao et al., 2018) can be loaded into metal NPs. The small size and stability of the metal NPs enhance the bioavailability of the drugs. Metal NP formulation containing a superparamagnetic iron oxide core coated with short- and long-chain polyethylene glycol (PEG) was reported. The hydrophobic paclitaxel and folic acid were coupled to a metallic core, and the PEG served as a hydrophilic outer layer. When compared to free paclitaxel, the NPs system delivered the drug at conditions that mimicked the acidic intracellular pH of breast cancer cells, and the folic conjugation resulted in higher NP absorption by target cells, which increased the cytotoxicity to target cells (Jeon et al., 2019). In another study, for colon target dual drug delivery, a chitosan/palladium nanocomposite was created. Curcumin (CUR) and 5-fluorouracil (5-FU) were loaded individually and in combination with chitosan/Pd nanocomposite. The growth of HT-29 cells is inhibited more effectively by co-encapsulated nanocomposite than by 5-FU, CUR monotherapy (Dhanavel et al., 2017). Some NP systems have higher IC50 values as compared to the free drug because of slow drug release, but the systems show sufficient credibility as targeted drug delivery systems (Pan et al., 2017). The comparison of IC50 values of the anticancer drugs-based metal NPs and their comparison with the free drug is given in Table 1.

Table 1.

Comparison of IC50 values of the anticancer drugs-based metal nanoparticles and their comparison with the free drug.

Nanoparticle type Cancer cell line IC50 value of nanoparticle system Anticancer drug IC50 value of free drug References
Resveratrol stabilized gold nanoparticles Glioma carcinoma cell line (LN 229) 4 μg/mL Doxorubicin 6 μg/mL Mohanty et al. (2014)
Multifunctional nanosystem (MFNCs) of gold nanorods, iron oxide nanoparticles, and gold nanoclusters assemblies within BSA nanoparticles HeLa cancer cells 2.3 μg/mL Doxorubicin 0.5 μg/mL Pan et al. (2017)
Gold nanoparticles based nanoconjugates Lung cancer cell line (H520) 25 µM Docetaxel 38 µM Thambiraj et al. (2019)
Gold nanoparticles Breast cancer cells MCF-7 30 ± 5 μg/mL Chloroquine >30 ± 5 μg/mL Joshi et al. (2012)
Silver nanoparticle HepG2 cells 1.92 μg/mL Epirubicin 0.11 μg/mL Ding et al. (2019)
Jacalin-capped silver nanoparticles Human chronic myeloid leukemia 100 nM Acetylshikonin (AS) and beta-dimethylacrylshikonin (BDS) 500 nM Ayaz Ahmed et al. (2016)
PEG capped silver nanoparticles Breast cancer cells MCF-7 258.6 μg/mL Methotrexate 512.7 μg/mL Muhammad et al. (2016)
Copper nanoparticles based systems Drug-resistant prostate cancer cell 85, 172, and 193 nM Paclitaxel (control) 2575 nM Chen et al. (2018)

2.4. Nanoparticles based hyperthermia

When biological materials are heated just a few degrees beyond their normal temperature, significant changes occur, including ceil death. Hyperthermia therapy is a type of cancer treatment in which bodily tissue is subjected to high temperatures, usually up to 113 degrees Fahrenheit (40–45 °C), in order to harm or kill cancer cells (Jose et al., 2020). All hyperthermia-related events aim to change the extracellular milieu by triggering immune responses and driving tumor cells to switch to an anaerobic metabolic system (Balivada et al., 2010). Hyperthermia is divided into three categories based on the site of application: whole-body hyperthermia, regional hyperthermia, and localized hyperthermia. Depending on the form of application, whole-body hyperthermia can be invasive or noninvasive. Invasive hyperthermia is the process of heating blood extracorporeally, whereas noninvasive hyperthermia is the process of increasing temperature through the use of hot air, hot wax, or RF or IR irradiation, which cannot be used to treat deep tumors (Wust et al., 2002). Hyperthermia in a specific area called regional hyperthermia uses noninvasive treatment (e.g. non-ionizing electromagnetic radiation (NIR) or ultrasound are used to heat regionally situated tumors) or invasive approaches (e.g. thermal conduction, or the use of magnetic implants) (Baker et al., 1982; Longo et al., 2016). The invasive or noninvasive procedures listed above are utilized to heat tiny tumors to a depth of 4 cm in the localized hyperthermia approach (Jose et al., 2020). Nanotechnology especially MNPs has created a huge opportunity to advance the field of hyperthermia. The heat dissipation processes of MNPs can be used to understand the mechanism of tumor-killing by hyperthermia. Magnetic NPs disperse heat to tumor cells through two processes: Neel relaxation and Brownian relaxation. Neel relaxation occurs when the magnetic moment reorients parallel to the applied magnetic field, whereas Brownian relaxation happens when the nanomaterial is mechanically rotated toward the external magnetic field. When a material is exposed to an external alternative magnetic field (AMF) with a magnetic field reversal time less than the material's magnetic relaxation period, both processes occur (Chen et al., 2017). High-grade superparamagnetic MnFe2O4 NPs were manufactured using a low-cost and environmentally friendly co-precipitation approach with the goal of hyperthermia application. The results showed that MnFe2O4 MNPs could reach hyperthermia temperature (42 °C) in 260 seconds at a low level of 0.4 g/mL, indicating that the material could be employed as a heating agent in magnetic hyperthermic treatment (Patade et al., 2020). Ma et al. reported Fe3O4–Pd Janus NPs with amplified dual-mode hyperthermia and enhanced ROS generation for breast cancer treatment. Under alternating magnetic field (AMF) plus laser irradiation, Fe3O4–Pd JNPs achieved a larger temperature enhancement than the corresponding individual modality (only AMF or laser irradiation alone for Fe3O4–Pd JNPs) or the total of two individual modalities. In the presence of H2O2 in an acidic environment, Fe3O4–Pd JNPs increased ROS generation due to the interface synergistic effect in creating hydroxyl radicals (OH), which was realized by Fe3O4 NP-based Fenton reaction and Pd nanosheet-based catalytic capabilities. Surprisingly, with external AMF + laser irradiation, the ROS level was raised even higher. On an orthotopic mouse breast cancer model, the anti-tumor activity of Fe3O4–Pd JNPs was tested in vivo. Under AMF with laser irradiation, guided by MRI/PA dual-mode imaging with excellent spatial resolution and precision, Fe3O4–Pd JNPs provided full tumor suppression without notable deleterious effects (Ma et al., 2019).

2.5. Radiotherapy treatment through nanoparticles

High-energy radiations are used in radiation therapy (RT) to inhibit the proliferation or kill malignant cells. Ionizing radiations are the type of primary concern for cancer treatment. Ionizing radiation is electromagnetic radiation with sufficient energy to ionize or remove electrons from atoms or molecules, resulting in the formation of ions. Ions with high kinetic energy collide several times, depositing a considerable amount of energy in the cells they travel through. The transferred energy is sufficient to stop tumor cells from replicating DNA or transcribing RNA, resulting in cell death. The most difficult aspect of radiotherapy is delivering a deadly dosage of radiation to tumor cells while preventing unintended cell damage (Fard et al., 2017; Song et al. 2017; Césaire et al. 2018; Richardson et al., 2018; Carozza et al. 2020). Metal NPs are widely employed in radiotherapy to increase the specificity of radiations to the targeted spot, reducing radiation dose and preventing toxicity and injury to normal tissues. Ionizing radiation causes the radiolysis of water molecules, resulting in the production of reactive oxygen species (ROS). They have a significant damaging effect on DNA due to the unpaired electron. Metal NPs use a variety of ways to improve radiation targeting. Metals increase tumor cell oxidative stress, promote selective apoptosis, and reduce clonogenic survival (Al-Musywel & Laref 2017; Choi et al., 2020; Igaz et al., 2020; Schuemann et al., 2020). Various metal NPs have been used in recent RT research; however, silver and gold NPs surpass other metal NPs for radio sensitization applications in cancer imaging and therapy due to their high atomic number and mass-energy coefficient. To cope with cancer, a synergistic treatment of ionization and hyperthermia is also effective. Simultaneous treatment that causes hyperthermia in tumor cells while also delivering radiations appears perfect, but hyperthermia prior to radiations is thought to be more successful. Inverse Metal NPs improve radiation targeting while also causing a hyperthermic response at the tumor location. When heat is combined with metal and RT for cancer, response rates increase by 16–26% (Cędrowska et al., 2020; Tolkaeva et al., 2021).

Sears et al. have shown that triple-negative breast cancer is sensitive to photothermal and ionizing radiation. Nanoparticles of silver having a peak absorbance in the near-infrared (NIR) spectrum were produced. The scientists tested the possibility of treating MDA-MB-231 TNBC cells selectively without harming nonmalignant MCF-10A breast cells using a multimodal method based on combination photothermal therapy, IR sensitization, and targeted cytotoxicity. There were no nonmalignant mammary epithelial cells saved as a result of this combination. It was shown that thermal radiation sensitization using triangular silver NPs resulted in excellent results despite the lower treatment dose and frequency (Sears et al., 2021), excellent results despite the lower treatment dose and frequency (Sears et al., 2021). When combined with the histone deacetylase inhibitor SAHA, gold NPs and radio sensitization were tested in 2D and 3D cancer cell cultures. Radiation-resistant A549 and DU-145 cancer cells were used to test the treatment's effectiveness. Prior to radiotherapy, gold NPs and SAHA dramatically reduced the number of live cells, which indicates that the combination of gold NPs and SAHA significantly boosted the potency of irradiation (Igaz et al., 2020).

3. Metal nanoparticles used for cancer therapy

Various metal NPs have been employed in cancer treatment. The metal NPs can be divided into noble and non-noble metals-based NPs. The role of some of the metal NPs in cancer treatment is highlighted in Table 2.

Table 2.

Potential of metal nanoparticles as cancer treatment.

Type of metal nanoparticles Targeted cancer Targeting role References
Glyco-gold nanoparticles Cervical cancer (HeLa and L929 cells) Conjugated RNase Zhao et al. (2021)
Silver nanoparticles Pancreatic cancer (PANC-1, AsPC-1, and MIA PaCa-2 cells) Oxygen based (ROS) or nitrogen based (RNS) reactive species Wang et al. (2021)
Mesoporous platinum nanoparticles Breast cancer (MCF-7/ADR cells) Photothermal therapy/doxorubicin Fu et al. (2020)
Superparamagnetic iron oxide nanoparticles Breast cancer bone metastasis (MDA-MB-231/ bone marrow cells) Bone-targeting peptide-conjugated Pang et al. (2021)
Nickel oxide nanoparticles Triple-negative breast cancer cells (Vero cell line and MDA-MB-231 cells) Folic acid decorated and pH-sensitive Binu et al. (2021)

3.1. Noble metals-based nanoparticles for cancer therapeutics

The noble metal is the metal from any of the several metallic chemical elements that have outstanding oxidation resistance, even at high temperatures. The main limitation with their application is the high cost of these metals. Noble metals commonly employed for NPs preparation include gold, silver, platinum, and palladium.

3.1.1. Gold nanoparticles

The non-reactive nature of gold makes it a noble element. Its resistance to chemical oxidation renders it impervious to degradation and corrosion. Thus, it can retain its form and luster for millennia. Gold NPs can be made in a variety of ways, including chemical, physical, biological, and green synthesis. The bottom-up and top-down approaches are used in all types. Gold NPs have a wide variety of biomedical applications due to their unique physicochemical characteristics (Chen et al., 2013). Recently, there has been a lot of discussion about tumor targeting. Gold-based metal NPs system along with their cancer-targeting properties have been elaborated in Figure 6. The anti-tumor effects of gold NPs can be further enhanced by surface functionalization or coating, and these NPs can be used for a variety of diagnostic, therapeutic, bioimaging, and prognostic purposes.

Figure 6.

Figure 6.

Gold nanoparticles physicochemical properties and functionalization against cancer.

Botteon et al. reported the biosynthesis of gold NPs and used a bee product called Brazilian red propolis (BRP). T24 bladder cancer and PC-3 prostate cancer cell lines were treated with biosynthetic gold NPs and exhibited substantial in vitro cytotoxic effects (Bray et al., 2018). Curcumin and isonicotinic acid hydrazide corona functionalized gold NPs were formulated to target cancer, according to Umapathi et al. (2020). Lung cancer cells (LK-2) and fibrillary epithelial cells (TIG-120) are particularly sensitive to the harmful effects of functional NPs. The generation of ROS by conjugating CUR and INH on AuNPs increased anticancer activity (ROS). When the investigation was extended, apoptosis and morphological changes in LK-2 and TIG-120 cells were identified. Additionally, the anticancer efficacy of these NPs is contrasted with that of traditional cisplatin (Botteon et al., 2021).

3.1.2. Silver nanoparticles

Silver NPs are becoming increasingly popular in biomedicine due to the wide range of applications they have, such as antimicrobial wound dressings, topical lotions to prevent infection, and anticancer therapies (Sondi & Salopek-Sondi, 2004). The primary mechanisms through which silver NPs function include ROS, oxidative stress, and DNA damage. ROS are essential for the survival of cells since they help to keep their internal balance in check. As a byproduct of cellular metabolism, ROS is a key player in signaling networks within cells. However, an excessive amount of intracellular ROS damages DNA, lipids, and proteins as a mechanism for silver NP-induced toxicity (Jain et al., 2021). Toxicity in treated cells is caused by the release of silver ions in the cytosol following endocytosis of silver NPs and their breakdown in an acidic environment. Thus, silver NPs have been linked to an increased risk of cancer and cell death due to their ability to interfere with the cell's basic metabolic and cell cycle pathways (De Matteis et al., 2015). Silver NPs functionalized paclitaxel nanocrystals boost the overall anti-cancer activity on human cancer cells, according to Muhammad et al. (2021). Nanocrystals were developed that combined the organic anti-cancer drug paclitaxel with inorganic silver NPs as tumor-targeting agents. The polydopamine (PDA) was applied to the paclitaxel nanocrystals, which were used as a template. Silver NPs and the tumor-targeting peptide NR1 were grafted onto the PDA layer, which was also a connecting bridge for manufacturing and depositing the silver NPs in situ (RGDARF). Drug nanocrystals coated with NR1/AgNP demonstrated dramatically improved cellular absorption efficiency, in vitro anti-cancer activity and an anti-migration effect against a range of cancer cells as a result. According to the data, silver NPs and paclitaxel had an additive or synergistic influence on each other, as well as on the NR1-receptor interaction, pH-responsive drug release, and the small size. In terms of selectivity and biocompatibility, these NR1-AgNP-decorated PTX nanocrystals were very well-balanced. The apoptotic efficacy of these nanocrystals was also high, resulting in lysis of the cell membrane as well as damage to the nucleus, dysfunction of the mitochondria, excessive production of ROS, and double-stranded DNA breakage. Authors proposed that P53 and caspase 3 activation, as well as Bax-to-Bcl-2 ratio modification, may be relevant to the putative acting mechanism and molecular basis of these distinct pharmacological nanocrystals (Umapathi et al., 2020; Muhammad et al., 2021).

3.1.3. Platinum nanoparticles

Patients are treated all around the world using platinum-based drugs like cisplatin, carboplatin, and oxaliplatin. However, the lack of specificity in cancer treatment leads to adverse effects and an increase in drug resistance (Mochida et al., 2017). Biotechnology, nanomedicine, and pharmacology all use platinum NPs in respective studies. Inorganic platinum NP nanoformulations are yet to be tested in humans. The longer the platinum NPs can circulate inside the body, the more beneficial it may be to coat their surfaces with a biocompatible substance like polyvinylpyrrolidone (PVP) (Jeyaraj et al., 2019). In a study, DOX was used as a model drug, to make PVP-functionalized platinum NPs with an octopod shape that demonstrated mono-dispersity. The system was used to improve drug distribution and reduce toxicity. It was found that both drug release and biocompatibility were improved with the platinum–DOX conjugate system. Two intrinsic breast cancer cell subtypes (MCF-7 and MDA-MB-231) were used to assess the system's cytotoxic capacity. The mechanisms involved in inhibiting the PI3K/AKT signaling pathway via activation of the tumor suppressor gene PTEN were found to be implicated (Patel et al., 2021). Kankala et al. postulated that platinum NPs can penetrate deep into tumors and have synergistic therapeutic effects because of the free radical species-assisted catalysis of platinum NPs. The ultrasmall platinum NPs were disseminated in chitosan loaded across zinc-doped mesoporous silica nanocarriers through a self-assembly mechanism. Doxorubicin molecules were loaded more efficiently into the tumor's acidic microenvironment by the zinc species doped in the siliceous frameworks, without the need for any additional functionalization. This strategy improved anticancer efficacy by dismantling the established coordination interactions between the host and guest species (Dhavale et al., 2021). The technique considerably aided tumor eradication by facilitating deep tumor penetration and simultaneously generating detrimental free radicals for the destruction of MDR malignancies (Kankala et al., 2020).

3.1.4. Palladium nanoparticles

Palladium NPs can be used in theragnostic applications because of their outstanding catalytic and optical capabilities. Palladium nanomaterial has been used as a prodrug activator, photothermal agent, and anticancer and/or antibacterial therapy, according to researchers. The multifunctional palladium NPs mediating photothermal therapy along with imaging have been presented in Figure 7.

Figure 7.

Figure 7.

Preparation (A), functionalization and tumor targeting (B) of palladium nanoparticles (Bharathiraja et al., 2017).

It has been claimed that palladium NPs can be biosynthesized cost-effectively utilizing Saudi propolis. With an IC50 of 104.79 µg/mL, palladium NPs successfully cured MCF-7 ductal cancer (Al-Fakeh et al., 2021). These palladium NPs have been modified to treat MCF7 breast cancer cells using PVP-functionalized palladium. PVP-palladium NPs dramatically reduced the viability of human breast cancer MCF7 cells at increasing doses. Caspase3/7 enzymatic activity was hypothesized to be the mechanism for the system's induction of death by causing damage to mitochondrial membrane potential and nuclear DNA (Ramalingam et al., 2020).

3.2. Non-noble metals-based nanoparticles for cancer therapeutics

Non-noble metals despite their prone nature to oxidation have many advantages like they are low cost, abundant, and possess good conductivity. The application of these metals in cancer therapeutics is described below.

3.2.1. Magnetic nanoparticles (iron/nickel)

The manipulation of MNPs is possible due to the use of external magnetic fields. Magnetic materials such as iron, nickel, or cobalt and functional chemicals are the most common components of these particles (Edis et al., 2021). A high-frequency magnetic field can elevate the temperature of the tumor to 40–46 °C by generating heat from these NPs. Another noteworthy potential of MNPs is their ability to combine heat (hyperthermia) with drug release in cancer treatment (Dwivedi et al., 2020). In a study, MNPs containing DOX–gelatin cores and Fe3O4–alginate shells were used to deliver targeted anticancer drugs. Doxorubicin was used as a model drug and implanted in the gelatin core to achieve excellent encapsulation efficiency. Controlled drug release was achieved by using an outer magnetic film, which could target the tumor tissue. These NPs were observed in the nucleus of MCF-7 breast cancer cells with an external magnetic field. Using an external magnetic field, the NPs efficiently targeted MCF-7 breast cancer cells, and after six hours of incubation, they appeared in the nuclei of those cells. MCF-7 cell viability declined to 52.3% after 12 hours of treatment, with relative fluorescence intensity of 98.4% (Huang et al., 2020). Anticancer drug telmisartan (TEL) was delivered to Fe3O4 magnetic nanoparticles (MNPs) via grafted chitosan, a naturally occurring hydrophilic and biodegradable polymer. Drug-loaded MNP-CS (MNP–CS–TEL) exhibited pH-responsive controlled release properties. The cytotoxicity of MNP–CS–TEL against PC-3 human prostate cancer cells was dose-dependent. The anticancer effects of the anticipated nano-formulation were found to be significant (Dhavale et al., 2021). The capacity to load large amounts of pharmaceuticals and control drug release are two advantages of adding MNPs into self-assembled hybrid NPs. In this context, NPs made of nickel ferrite (NFO) have been used to deliver anti-cancer drugs. Poly vinyl alcohol/stearic acid hybrid with NFO-containing PEG was used for zidovudine (AZT) distribution. AZT was intracellular delivery confirmed via NFO-reinforced hybrid NPs (Joshy et al., 2020). An emphasis is also placed on the green chemistry-based fabrication of MNPs. The green synthesis of nickel oxide NPs in Arabic gum was reported. To test the cytotoxicity of nickel oxide NPs, they used the MTT method on cancer U87MG cell lines. For U87MG cancer cells, the IC50 of this compound was 37.84 g mL (Sabouri et al., 2021).

3.2.2. Zinc oxide nanoparticles

One of the most common metallic NPs in the world is zinc oxide. Zinc oxide NPs have received a lot of attention recently because of their ability to produce ROS when exposed to light. Particles of zinc oxide can be modified chemically to increase their photocatalytic efficiency as well as their ability to generate ROS by a variety of methods including doping with metals, polymer modification, and organic photosensitizing agents. The improved antibacterial and anticancer activity of modified zinc oxide NPs can be attributed to their increased ROS generation efficiency (Sivakumar et al., 2018). The potential anticancer activity of the CUR-loaded zinc oxide NPs was investigated using the MTT assay on the rhabdomyosarcoma RD cell line, while their cytotoxic effects were assessed using the resazurin assay on human embryonic kidney cells. The large aspect ratio of ZnO structures was considered a factor in the NPs' increased cytotoxicity (Perera et al., 2020). In another study, it was reported that egg albumin was used in the biosynthesis of zinc oxide NPs. The system showed anticancer efficacy on MCF-7 as measured by the MTT assay, with considerable cytotoxicity and correspondingly reduced cellular viability. The prepared NPs induced ROS, which increased the regulated transcription of mRNA levels of apoptotic genes such as p53, bcl-2, caspase-3, and caspase-9 while drastically downregulating the expression of anti-apoptotic gene Bcl-2, according to a gene expression research (RT-PCR) and western blot analysis. The findings suggested that the nano system specifically suppressed MCF-7 gene expression via ROS damage and cell death induced by cytotoxicity (Vijayakumar et al., 2020).

3.2.3. Copper nanoparticles

Copper is a necessary component of plant and animal metabolism. Naturally, it is a soft, moldable, and easy to bend substance, with high thermal and electrical conductivities. When compared to analogous other metals, such as platinum, silver, and gold, copper NPs are cheaper among the transition metals under consideration (Rayapa Reddy, 2017). Green synthesized is also emphasized for copper NPs in recent trends. Broccoli green extract was described as a green and environmentally friendly precursor for copper NP one-pot biosynthesis. The developed formulation was proven to be beneficial in the treatment of prostate cancer (Prasad et al., 2016). The cytotoxicity of a chitin-based silver and copper nanocomposite against human breast cancer (MCF-7) cells was investigated. The inhibitory concentration (IC50) of the system was found to be 31 mg. Further findings revealed an increase in ROS production, decreased antioxidant enzyme activity, and membrane integrity degradation, confirming the cellular cytotoxic effect of the copper–silver NPs-based nanocomposite (Solairaj et al., 2017).

3.2.4. Cerium Oxide nanoparticles

Cerium oxide NPs surrounded by an oxygen lattice, have shown potential in a variety of applications. These can induce apoptosis in the cancer cells (Gao et al., 2014). Through oxidative activation of the JNK apoptotic pathway, cerium oxide NPs make pancreatic cancer more sensitive to RT. Cerium oxide NPs cause cancer cells to produce more ROS. The oxidation of thioredoxin 1 (TRX1), which results in the activation of apoptosis signaling kinase 1, was demonstrated to be triggered by ROS (ASK1). Enhanced JNK activation was thought to be the outcome of increased TRX1 oxidation, based on the increase in ASK1 activation after co-treatment with Cerium oxide NPs followed by RT (Wason, 2018).

3.2.5. Titanium nanoparticles

Natural forms of titanium dioxide include the inert minerals, anatase, brookite, and rutile, all of which occur in varying degrees of abundance. There are a lot of approaches to synthesize titanium dioxide NPs, including physical and chemical. These methods of nanomaterial synthesis have some shortcomings, including cost, low biocompatibility, and several secondary toxicities, as well as substantial environmental biosafety problems. As far as NP synthesis is concerned, biogenesis has been suggested. The biogenesis of titanium dioxide NPs uses a variety of organisms, including bacteria, algae, fungi, and plant materials. Biogenic titanium dioxide NPs have a unique size, shape, and biochemical functional corona that allows them to execute therapeutic effects at the molecular level, such as anticancer, antibacterial, antioxidant, larvicidal, and photocatalysis (Ikram et al., 2021). The use of titanium dioxide NPs in photothermal therapy for a melanoma cancer model was described by Muhammad et al. In the in vivo model, the average tumor size in the mice getting titanium dioxide-PEG NPs with laser excitation treatment decreased significantly compared to the mice receiving laser therapy alone (Behnam et al., 2018).

3.2.6. Magnesium nanoparticles

Superparamagnetic magnesium ferrite-based NPs are used as radiosensitizers. Bio-nanocomposites and NPs systems have been proposed to combat cancer (Ansari Moghaddam et al., 2017; Mangalampalli et al., 2019; Kgosiemang et al., 2020).

4. In vivo application of metal nanoparticles

Several studies have been reported to check the anticancer effect of the metal NPs on tumor growth within animal models. Sriram et al. demonstrated the anticancer efficacy of biologically produced silver NPs in vivo using Dalton's lymphoma ascites. Silver NPs enhanced survival duration in the tumor mouse model by almost 50% as compared to tumor controls. Additionally, silver NPs reduced the volume of ascitic fluid in tumor-bearing animals by 65%, restoring normal body weight. The tumor volume was around 7.3 mL in control mice but was considerably reduced to 2.6 mL in the group treated for 15 days with silver NPs at a dosage of 500 nM (Sriram et al., 2010). In another study, selective radio-sensitization of brain tumors using gold NPs was checked on mice. The successful treatment of brain cancers such as glioblastoma multiforme (GBM) is constrained in large part by the cumulative dose of RT that may be safely administered and by the blood–brain barrier (BBB), which prevents the systemic anticancer medicines from reaching tumor tissue. Hence, the developed NPs exhibited that mice treated with gold NPs followed by RT had a longer median survival time (28 days on average) compared to mice treated with RT for only 14 days (p=.011). In general, mice treated with dual modalities maintained a higher level of normal activity and lost less weight than untreated or single-modality mice. The authors implied the successful extravasation of the gold NPs into the brain as a result of tumor-induced rupture of the BBB, where it radio-sensitized tumor cells to RT, resulting in enhanced tumor cell death and survival (Joh et al., 2013). Bis(2,4-pentanedionato)copper(II) encapsulated chitosan NPs were analyzed on mice model with control group having 1200 mm3 of tumor volume. The dose of 2000 μg/kg of body weight of both non-targeted and targeted NPs reduced tumor volume to 600 mm3 and 125 mm3, respectively (Bhanumathi et al., 2018) (Table 3).

Table 3.

Comparison of tumor growth with metal nanoparticles and clinical drugs.

Type of nanoparticle Animal model Dose of the nanoparticle system Effect of nanoparticle system on tumor growth Control group (drug) Dose of drug Effect of drug on tumor growth References
Doxorubicin loaded superparamagnetic iron oxide nanoparticles Mice Equivalent to 0.64 mg/kg doxorubicin 63% reduction Doxorubicin 5 mg/kg 38% reduction Yu et al. (2008)
RGD-modified apoferritin nanoparticles Athymic nude mice Equivalent to 10 mg/kg doxorubicin 89.6% tumor growth inhibition Doxorubicin 10 mg/kg 74.0% Zhen et al. (2013)
Platinum nanoparticles K562-xenografted nude mice Tumor volume reduction to ∼31.18 ± 3.42% 1 mg/kg Cisplatin 1 mg/kg Tumor volume reduction to 53.72 ± 5.60% Zeng et al. (2020)
Folic acid- and berberine-loaded silver nanomaterial Mice (control group tumor volume of 1287.27 ± 0.12 mm3) Tumor volume of 101 mm3 5 mg/kg body weight Berberine 5 mg/kg body weight Tumor volume of 470 mm3 Bhanumathi et al. (2018)

5. Risk factors involved in the clinical application of metal nanoparticles

Nanoparticles have been found and produced in large numbers, but conventional criteria for limiting exposure and assessing their potential toxicity are lacking (Medici et al., 2021). Toxic effects are possible despite the particular advantages of nanomaterials due to their tiny size and high surface area which have been shown to boost reactivity with biological targets. Consumer and industrial products based on nanotechnology are nevertheless plagued by a slew of safety and sustainability issues (Grieger, 2019). Numerous problems regarding the safety and long-term sustainability of consumer and industrial goods based on nanotechnology remain unresolved (Najahi-Missaoui et al., 2021). Figure 8 depicts the various methods by which NPs might enter the body. Inflammation, genotoxicity, and organelle failure in cells are all directly linked to oxidative stress, which regulates the toxicity of NPs. The activation of oxidative enzymatic pathways results in the creation of nitrogen or oxygen-based free radicals, which in turn causes oxidative stress. Protein, DNA, and lipid damage, as well as mitochondrial and endoplasmic reticulum dysfunction and eventually apoptosis or ferroptosis, occur as a result of the relative imbalance or failure of the intracellular free radical scavenging mechanism's defense capability under prolonged oxidative stress (Reuter et al., 2010; Liao et al., 2020; Zhang et al., 2020).

Figure 8.

Figure 8.

Exposure routes, ways of uptake, translocation, and distribution of NPs into the human body (Medici et al., 2021).

The clinical application of the metal NPs can be achieved only if the risks and toxicity are controlled, from production to treatment. In a study, it was discussed that silver binds strongly to sulfur (both organic and inorganic) in natural systems (fresh and sea waters) as well as wastewater. Due to the decreased solubility of silver sulfide, sulfidation of silver NPs reduces their toxicity significantly, potentially limiting their short-term environmental impact (Liao et al., 2020). The manufacturing process of NPs is proposed by green synthesis utilizing plants, fungi, bacteria, and algae to avoid the high rate of harmful compounds and the severe environmental conditions used in chemical and physical processes. When compared to physical and chemical methods of synthesis, the green route of synthesis appeared to be safer and more environmentally friendly (Levard et al., 2012; Kalpana & Rajeswari, 2018). Copper NPs were synthesized by mixing copper acetate solution with Eclipta prostrata leaf extract without utilizing any surfactant or external energy. The antioxidant and cytotoxic properties of copper NPs made from Eclipta prostrata leaves extract were examined. E. prostrata leaf extract was reported as a good copper ion reducer, and the biosynthesized copper NPs were less harmful to the environment. The cytotoxicity of produced copper NPs against HepG2 cells was demonstrated in in vitro anticancer tests (Chung et al., 2017). The toxicity of NPs can also be reduced by using various polymers to coat metal NPs. To transfer cisplatin prodrug (DSP) to the bone, PEG coated NPs formed of a Zn2+ coordination polymer were coupled with a bone-seeking moiety, alendronate (ALN). In vivo biodistribution experiments revealed that DSP-Zn@PEG-ALN NPs intravenously delivered roughly fourfold more platinum to bone metastatic lesions than to healthy bones (He et al., 2017).

6. Conclusions and future perspective

Chemotherapy for cancer is still the most challenging area for academics looking for better clinical results. The use of targeted drug delivery for the treatment of cancer has the potential to improve efficacy while lowering the adverse and side effects. Nanotechnology has revolutionized medical research. The metal NPs are among the candidates for next-generation anticancer treatment. Metal NPs have been extensively studied due to their remarkable flexible physical and chemical properties. The current research has led to achieving various advantages with metal NPs including low cost, ease of synthesis, and the flexibility to control the form and size of the NPs. Green synthesis has also eliminated the risk of harsh and environmentally unfriendly compounds and solvents. Furthermore, due to their unique plasmonic properties, noble metal NPs provide a reliable means of tracking nano-complex therapeutic carriers within the body, allowing for a more efficient therapy with a lower chance of side effects than traditional therapies. These NPs would allow practitioners to diagnose and track the progress of treatment during treatment. Additionally, non-noble metal NPs are cost-effective and possess specific properties like hyperthermia and magnetic properties.

Several studies have demonstrated the efficacy of metal NPs as a future of cancer treatment, and many metal NP compositions are currently in preclinical and clinical trials. But a lot of concerns need to be addressed yet. The tumor imaging will be done with metal NPs to determine its exact stage, and tumor therapeutic methods will be developed in which the toxicity levels (prevalent in existing approaches) are completely eradicated. However, various criteria related to their manufacturing and use must be examined before they can be used in clinical trials. These precautions include control of techniques of preparation, repeatability, stability, dose, level of accumulation at the target and off-target sites, and, most critically, toxicological hazards. The regulatory agencies must play an important role in creating new criteria for clinical use of metal NPs in cancer treatment and drug delivery, as well as new approaches to evaluate the efficiency and safety measures of such NPs. On top of that, research scientists are struggling to come up with optimum amounts of phytochemical conjugated metal NPs for cancer patients and the most effective means of administering these doses. Metal NPs, on the other hand, will undoubtedly become a major clinical tool in the fight against cancer once these concerns are resolved.

Funding Statement

This work was supported by the National Natural Science Foundation of China (No. 81802674 to JJX), Natural Science Foundation of Zhejiang Province (No. LY21H160049 to JJX), and Medical Health Science and Technology Project of Zhejiang Provincial Health Commission (No. 2021KY482, No. 2020KY008 to JJX).

Disclosure statement

No potential conflict of interest was reported by the author(s).

References

  1. Ahluwalia J, Avram MM, Ortiz AE. (2020). The evolving story of laser therapeutics for basal cell carcinoma. Dermatol Surg 46:1045–53. [DOI] [PubMed] [Google Scholar]
  2. Al-Fakeh MS, Osman SOM, Gassoumi M, et al. (2021). Characterization, antimicrobial and anticancer properties of palladium nanoparticles biosynthesized optimally using Saudi propolis. Nanomaterials 11:2666. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Al-Musywel HA, Laref A. (2017). Effect of gold nanoparticles on radiation doses in tumor treatment: a Monte Carlo study. Lasers Med Sci 32:2073–80. [DOI] [PubMed] [Google Scholar]
  4. Ansari Moghaddam S, Rahmani F, Delirezh N. (2017). Investigating the effects of magnesium oxide nanoparticle toxicity on K562 blood type cancer cells. Armaghane Danesh 22:584–94. [Google Scholar]
  5. Ayaz Ahmed KB, Mahapatra SK, Charan Raja MR, et al. (2016). Jacalin-capped silver nanoparticles minimize the dosage use of the anticancer drug, shikonin derivatives, against human chronic myeloid leukemia. RSC Adv 6:18980–9. [Google Scholar]
  6. Baker HW, Snedecor PA, Goss JC, et al. (1982). Regional hyperthermia for cancer. Am J Surg 143:586–90. [DOI] [PubMed] [Google Scholar]
  7. Balivada S, Rachakatla RS, Wang H, et al. (2010). A/C magnetic hyperthermia of melanoma mediated by iron(o)/iron oxide core/shell magnetic nanoparticles: a mouse study. BMC Cancer 10:119. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Behnam MA, Emami F, Sobhani Z, Dehghanian AR. (2018). The application of titanium dioxide (TiO2) nanoparticles in the photo-thermal therapy of melanoma cancer model. Iran J Basic Med Sci 21:1133. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Bhanumathi R, Manivannan M, Thangaraj R, Kannan S. (2018). Drug-carrying capacity and anticancer effect of the folic acid- and berberine-loaded silver nanomaterial to regulate the AKT-ERK pathway in breast cancer. ACS Omega 3:8317–28. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Bharathiraja S, Bui NQ, Manivasagan P, et al. (2017). Multimodal tumor-homing chitosan oligosaccharide-coated biocompatible palladium nanoparticles for photo-based imaging and therapy. Sci Rep 8:1–16. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Bidkar AP, Sanpui P, Ghosh SS. (2017). Efficient induction of apoptosis in cancer cells by paclitaxel-loaded selenium nanoparticles. Nanomedicine 12:2641–52. [DOI] [PubMed] [Google Scholar]
  12. Binu NM, Prema D, Prakash J, et al. (2021). Folic acid decorated pH sensitive polydopamine coated honeycomb structured nickel oxide nanoparticles for targeted delivery of quercetin to triple negative breast cancer cells. Colloids Surf A Physicochem Eng Asp 630:127609. [Google Scholar]
  13. Botteon CEA, Silva LB, Ccana-Ccapatinta G, Silva TS. (2021). Biosynthesis and characterization of gold nanoparticles using Brazilian red propolis and evaluation of its antimicrobial and anticancer activities. Sci Rep 11:1–16. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Bray F, Ferlay J, Soerjomataram I, et al. (2018). Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68:394–424. [DOI] [PubMed] [Google Scholar]
  15. Cancer . (2022). [Online]. Available at: https://www.who.int/news-room/fact-sheets/detail/cancer [last accessed 2022 Jan 22].
  16. Carozza JA, Böhnert V, Nguyen KC, et al. (2020). Extracellular cGAMP is a cancer cell-produced immunotransmitter involved in radiation-induced anti-cancer immunity. Nat Cancer 1:184–96. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Cędrowska E, Pruszyński M, Gawęda W, et al. (2020). Trastuzumab conjugated superparamagnetic iron oxide nanoparticles labeled with 225Ac as a perspective tool for combined α-radioimmunotherapy and magnetic hyperthermia of HER2-positive breast cancer. Molecules 25:1025. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Césaire M, Thariat J, Candéias SM, et al. (2018). Combining PARP inhibition, radiation, and immunotherapy: a possible strategy to improve the treatment of cancer? Int J Mol Sci 19:3793. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Çeşmeli S, Avci CB. (2019). Application of titanium dioxide (TiO2) nanoparticles in cancer therapies. J Drug Target 27:762–6. [DOI] [PubMed] [Google Scholar]
  20. Chen L, Chen C, Wang P, Song T. (2017). Mechanisms of cellular effects directly induced by magnetic nanoparticles under magnetic fields. J Nanomater 2017:1–13. [Google Scholar]
  21. Chen W-H, Xu X-D, Jia H-Z, et al. (2013). Therapeutic nanomedicine based on dual-intelligent functionalized gold nanoparticles for cancer imaging and therapy in vivo. Biomaterials 34:8798–807. [DOI] [PubMed] [Google Scholar]
  22. Chen W, Yang W, Chen P, et al. (2018). Disulfiram copper nanoparticles prepared with a stabilized metal ion ligand complex method for treating drug-resistant prostate cancers. ACS Appl Mater Interfaces 10:41118–28. [DOI] [PubMed] [Google Scholar]
  23. Choi J, Kim G, Bin Cho S, Im HJ. (2020). Radiosensitizing high-Z metal nanoparticles for enhanced radiotherapy of glioblastoma multiforme. J Nanobiotechnol 18:122. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Chung I-M, Rahuman AA, Marimuthu S, et al. (2017). Green synthesis of copper nanoparticles using Eclipta prostrata leaves extract and their antioxidant and cytotoxic activities. Exp Ther Med 14:18–24. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Dang Y, Guan J. (2020). Nanoparticle-based drug delivery systems for cancer therapy. Smart Mater Med 1:10–9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. De Matteis V, Malvindi MA, Galeone A, et al. (2015). Negligible particle-specific toxicity mechanism of silver nanoparticles: the role of Ag+ ion release in the cytosol. Nanomedicine 11:731–9. [DOI] [PubMed] [Google Scholar]
  27. Dhanavel S, Nivethaa EAK, Narayanan V, Stephen A. (2017). In vitro cytotoxicity study of dual drug loaded chitosan/palladium nanocomposite towards HT-29 cancer cells. Mater Sci Eng C Mater Biol Appl 75:1399–410. [DOI] [PubMed] [Google Scholar]
  28. Dhavale RP, Dhavale RP, Sahoo SC, et al. (2021). Chitosan coated magnetic nanoparticles as carriers of anticancer drug telmisartan: pH-responsive controlled drug release and cytotoxicity studies. J Phys Chem Solids 148:109749. [Google Scholar]
  29. Di Pietro P, Zaccaro L, Comegna D, et al. (2016). Silver nanoparticles functionalized with a fluorescent cyclic RGD peptide: a versatile integrin targeting platform for cells and bacteria. RSC Adv 6:112381–92. [Google Scholar]
  30. Ding J, Chen G, Chen G, et al. (2019). One-pot synthesis of epirubicin-capped silver nanoparticles and their anticancer activity against HepG2 cells. Pharmaceutics 11:123. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Dwivedi P, Kiran S, Han S, et al. (2020). Magnetic targeting and ultrasound activation of liposome–microbubble conjugate for enhanced delivery of anticancer therapies. ACS Appl Mater Interfaces 12:23737–51. [DOI] [PubMed] [Google Scholar]
  32. Edis Z, Wang J, Waqas MK, et al. (2021). Nanocarriers-mediated drug delivery systems for anticancer agents: an overview and perspectives. Int J Nanomedicine 16:1313–30. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Fard AE, Tavakoli MB, Salehi H, Emami H. (2017). Synergetic effects of docetaxel and ionizing radiation reduced cell viability on MCF-7 breast cancer cell. Appl Cancer Res 37:29. [Google Scholar]
  34. Farzin A, Etesami SA, Quint J, et al. (2020). Magnetic nanoparticles in cancer therapy and diagnosis. Adv Healthc Mater 9:e1901058. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Fernandes AR, Baptista PV. (2017). Gene silencing using multifunctionalized gold nanoparticles for cancer therapy. Methods Mol Biol 1530:319–36. [DOI] [PubMed] [Google Scholar]
  36. Fu B, Dang M, Tao J, et al. (2020). Mesoporous platinum nanoparticle-based nanoplatforms for combined chemo-photothermal breast cancer therapy. J Colloid Interface Sci 570:197–204. [DOI] [PubMed] [Google Scholar]
  37. Gao L, Yu J, Liu Y, et al. (2018). Tumor-penetrating peptide conjugated and doxorubicin loaded T1–T2 dual mode MRI contrast agents nanoparticles for tumor theranostics. Theranostics 8:92–108. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Gao Y, Chen K, Ma J, Gao F. (2014). Cerium oxide nanoparticles in cancer. Onco Targets Ther 7:835–40. [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Grieger K, Jones JL, Hansen SF, et al. (2019). Best practices from nano-risk analysis relevant for other emerging technologies. Nat Nanotechnol 14:998–1001. [DOI] [PubMed] [Google Scholar]
  40. He Y, Huang Y, Huang Z, et al. (2017). Bisphosphonate-functionalized coordination polymer nanoparticles for the treatment of bone metastatic breast cancer. J Control Release 264:76–88. [DOI] [PubMed] [Google Scholar]
  41. Hossen S, Hossain MK, Basher MK, et al. (2019). Smart nanocarrier-based drug delivery systems for cancer therapy and toxicity studies: a review. J Adv Res 15:1–18. [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. Huang C-H, Chuang T-J, Ke C-J, Yao C-H. (2020). Doxorubicin–gelatin/Fe3O4–alginate dual-layer magnetic nanoparticles as targeted anticancer drug delivery vehicles. Polymers 12:1747. [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Igaz N, Szőke K, Kovács D, et al. (2020). Synergistic radiosensitization by gold nanoparticles and the histone deacetylase inhibitor SAHA in 2D and 3D cancer cell cultures. Nanomaterials 10:158. [DOI] [PMC free article] [PubMed] [Google Scholar]
  44. Ikram M, Javed B, Hassan SWU, et al. (2021). Therapeutic potential of biogenic titanium dioxide nanoparticles: a review on mechanistic approaches. Nanomedicine 16:1429–46. [DOI] [PubMed] [Google Scholar]
  45. Jain N, Jain P, Rajput D, Patil UK. (2021). Green synthesized plant-based silver nanoparticles: therapeutic prospective for anticancer and antiviral activity. Micro Nano Syst Lett 9:1–24. [Google Scholar]
  46. Jeon M, Lin G, Stephen ZR, et al. (2019). Paclitaxel-loaded iron oxide nanoparticles for targeted breast cancer therapy. Adv Ther 2:1900081. [Google Scholar]
  47. Jeyaraj M, Gurunathan S, Qasim M, et al. (2019). A comprehensive review on the synthesis, characterization, and biomedical application of platinum nanoparticles. Nanomaterials 9:1719. [DOI] [PMC free article] [PubMed] [Google Scholar]
  48. Joh DY, Sun L, Stangl M, et al. (2013). Selective targeting of brain tumors with gold nanoparticle-induced radiosensitization. PLOS One 8:e62425. [DOI] [PMC free article] [PubMed] [Google Scholar]
  49. Jose J, Kumar R, Harilal S, et al. (2020). Magnetic nanoparticles for hyperthermia in cancer treatment: an emerging tool. Environ Sci Pollut Res Int 27:19214–25. [DOI] [PubMed] [Google Scholar]
  50. Joshi P, Chakraborti S, Ramirez-Vick JE, et al. (2012). The anticancer activity of chloroquine-gold nanoparticles against MCF-7 breast cancer cells. Colloids Surf B Biointerfaces 95:195–200. [DOI] [PubMed] [Google Scholar]
  51. Joshy KS, Augustine R, Mayeen A, et al. (2020). NiFe2O4/poly(ethylene glycol)/lipid–polymer hybrid nanoparticles for anti-cancer drug delivery. New J Chem 44:18162–72. [Google Scholar]
  52. Kalpana VN, Rajeswari VD. (2018). A review on green synthesis, biomedical applications, and toxicity studies of ZnO NPs. Bioinorg Chem Appl 2018:3569758. [DOI] [PMC free article] [PubMed] [Google Scholar]
  53. Kankala RK, Liu CG, Yang DY, et al. (2020). Ultrasmall platinum nanoparticles enable deep tumor penetration and synergistic therapeutic abilities through free radical species-assisted catalysis to combat cancer multidrug resistance. Chem Eng J 383:123138. [Google Scholar]
  54. Kgosiemang IK, Lefojane R, Direko P, et al. (2020). Green synthesis of magnesium and cobalt oxide nanoparticles using Euphorbia tirucalli: characterization and potential application for breast cancer inhibition. Inorg Nano-Metal Chem 50:1070–80. [Google Scholar]
  55. Levard C, Hotze EM, Lowry GV, Brown JGE. (2012). Environmental transformations of silver nanoparticles: impact on stability and toxicity. Environ Sci Technol 46:6900–14. [DOI] [PubMed] [Google Scholar]
  56. Liao C, Jin Y, Li Y, Tjong SC. (2020). Interactions of zinc oxide nanostructures with mammalian cells: cytotoxicity and photocatalytic toxicity. Int J Mol Sci 21:6305. [DOI] [PMC free article] [PubMed] [Google Scholar]
  57. Liu J, Wu T, Lu X, et al. (2019). A self-assembled platform based on branched DNA for sgRNA/Cas9/antisense delivery. J Am Chem Soc 141:19032–7. [DOI] [PubMed] [Google Scholar]
  58. Lok C-N, Zou T, Zhang J-J, et al. (2014). Controlled-release systems for metal-based nanomedicine: encapsulated/self-assembled nanoparticles of anticancer gold(III)/platinum(II) complexes and antimicrobial silver nanoparticles. Adv Mater 26:5550–7. [DOI] [PubMed] [Google Scholar]
  59. Longo TA, Gopalakrishna A, Tsivian M, et al. (2016). A systematic review of regional hyperthermia therapy in bladder cancer. Int J Hyperthermia 32:381–9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  60. Ma X, Wang Y, Liu X-L, et al. (2019). Fe3O4–Pd Janus nanoparticles with amplified dual-mode hyperthermia and enhanced ROS generation for breast cancer treatment. Nanoscale Horiz 4:1450–9. [Google Scholar]
  61. Mangalampalli B, Dumala N, Grover P. (2019). Toxicity assessment of magnesium oxide nano and microparticles on cancer and non-cancer cell lines. Nucleus 62:227–41. [Google Scholar]
  62. Mattiuzzi C, Lippi G. (2019). Current cancer epidemiology. J Epidemiol Glob Health 9:217. [DOI] [PMC free article] [PubMed] [Google Scholar]
  63. Medici S, Peana M, Pelucelli A, Zoroddu MA. (2021). An updated overview on metal nanoparticles toxicity. Semin Cancer Biol 76:17–26. [DOI] [PubMed] [Google Scholar]
  64. Mochida Y, Cabral H, Kataoka K. (2017). Polymeric micelles for targeted tumor therapy of platinum anticancer drugs. Expert Opin Drug Deliv 14:1423–38. [DOI] [PubMed] [Google Scholar]
  65. Mohanty RK, Thennarasu S, Mandal AB. (2014). Resveratrol stabilized gold nanoparticles enable surface loading of doxorubicin and anticancer activity. Colloids Surf B Biointerfaces 114:138–43. [DOI] [PubMed] [Google Scholar]
  66. Muhammad N, Zhao H, Song W, et al. (2021). Silver nanoparticles functionalized paclitaxel nanocrystals enhance overall anti-cancer effect on human cancer cells. Nanotechnology 32:85105. [DOI] [PubMed] [Google Scholar]
  67. Muhammad Z, Raza A, Ghafoor S, et al. (2016). PEG capped methotrexate silver nanoparticles for efficient anticancer activity and biocompatibility. Eur J Pharm Sci 91:251–5. [DOI] [PubMed] [Google Scholar]
  68. Najahi-Missaoui W, Arnold RD, Cummings BS. (2021). Safe nanoparticles: are we there yet? Int J Mol Sci 22:385. [DOI] [PMC free article] [PubMed] [Google Scholar]
  69. Pan UN, Khandelia R, Sanpui P, et al. (2017). Protein-based multifunctional nanocarriers for imaging, photothermal therapy, and anticancer drug delivery. ACS Appl Mater Interfaces 9:19495–501. [DOI] [PubMed] [Google Scholar]
  70. Pang Y, Su L, Fu Y, et al. (2021). Inhibition of furin by bone targeting superparamagnetic iron oxide nanoparticles alleviated breast cancer bone metastasis. Bioact Mater 6:712–20. [DOI] [PMC free article] [PubMed] [Google Scholar]
  71. Patade SR, Andhare DD, Somvanshi SB, et al. (2020). Self-heating evaluation of superparamagnetic MnFe2O4 nanoparticles for magnetic fluid hyperthermia application towards cancer treatment. Ceram Int 46:25576–83. [Google Scholar]
  72. Patel P, Umapathy D, Manivannan S, et al. (2021). A doxorubicin–platinum conjugate system: impacts on PI3K/AKT actuation and apoptosis in breast cancer cells. RSC Adv 11:4818–28. [DOI] [PMC free article] [PubMed] [Google Scholar]
  73. Perera WPTD, Dissanayake RK, Ranatunga UI, et al. (2020). Curcumin loaded zinc oxide nanoparticles for activity-enhanced antibacterial and anticancer applications. RSC Adv 10:30785–95. [DOI] [PMC free article] [PubMed] [Google Scholar]
  74. Pissuwan D, Valenzuela SM, Cortie MB. (2006). Therapeutic possibilities of plasmonically heated gold nanoparticles. Trends Biotechnol 24:62–7. [DOI] [PubMed] [Google Scholar]
  75. Prasad PR, Kanchi S, Naidoo EB. (2016). In-vitro evaluation of copper nanoparticles cytotoxicity on prostate cancer cell lines and their antioxidant, sensing and catalytic activity: one-pot green approach. J Photochem Photobiol B 161:375–82. [DOI] [PubMed] [Google Scholar]
  76. Pugazhendhi A, Edison TNJI, Karuppusamy I, Kathirvel B. (2018). Inorganic nanoparticles: a potential cancer therapy for human welfare. Int J Pharm 539:104–11. [DOI] [PubMed] [Google Scholar]
  77. Ramalingam V, Raja S, Harshavardhan M. (2020). In situ one-step synthesis of polymer-functionalized palladium nanoparticles: an efficient anticancer agent against breast cancer. Dalton Trans 49:3510–8. [DOI] [PubMed] [Google Scholar]
  78. Rayapa Reddy T. (2017). Green synthesis, morphological and optical studies of CuO nanoparticles. J Mol Struct 1150:553–7. [Google Scholar]
  79. Reuter S, Gupta SC, Chaturvedi MM, Aggarwal BB. (2010). Oxidative stress, inflammation, and cancer: how are they linked? Free Radic Biol Med 49:1603–16. [DOI] [PMC free article] [PubMed] [Google Scholar]
  80. Richardson D, Cardis E, Daniels RD, et al. (2018). Site-specific solid cancer mortality after exposure to ionizing radiation: a cohort study of workers (INWORKS). Epidemiology 29:31–40. [DOI] [PMC free article] [PubMed] [Google Scholar]
  81. Rivas-Domínguez A, Pastor N, Martínez-López L, et al. (2021). The role of DNA damage response in dysbiosis-induced colorectal cancer. Cells 10:1934. [DOI] [PMC free article] [PubMed] [Google Scholar]
  82. Sabouri Z, Akbari A, Hosseini HA, et al. (2021). Green-based bio-synthesis of nickel oxide nanoparticles in Arabic gum and examination of their cytotoxicity, photocatalytic and antibacterial effects. Green Chem Lett Rev 14:402–12. [Google Scholar]
  83. Schuemann J, Bagley AF, Berbeco R, et al. (2020). Roadmap for metal nanoparticles in radiation therapy: current status, translational challenges, and future directions. Phys Med Biol 65:21RM02. [DOI] [PubMed] [Google Scholar]
  84. Sears J, Swanner J, Fahrenholtz CD, et al. (2021). Combined photothermal and ionizing radiation sensitization of triple-negative breast cancer using triangular silver nanoparticles. Int J Nanomedicine 16:851–65. [DOI] [PMC free article] [PubMed] [Google Scholar]
  85. Singhal S, Nie S, Wang MD. (2010). Nanotechnology applications in surgical oncology. Annu Rev Med 61:359–73. [DOI] [PMC free article] [PubMed] [Google Scholar]
  86. Sivakumar P, Lee M, Kim Y-S, Shim MS. (2018). Photo-triggered antibacterial and anticancer activities of zinc oxide nanoparticles. J Mater Chem B 6:4852–71. [DOI] [PubMed] [Google Scholar]
  87. Skoetz N, Will A, Monsef I, et al. (2017). Comparison of first-line chemotherapy including escalated BEACOPP versus chemotherapy including ABVD for people with early unfavourable or advanced stage Hodgkin lymphoma. Cochrane Database Syst Rev 5:CD007941. [DOI] [PMC free article] [PubMed] [Google Scholar]
  88. Solairaj D, Rameshthangam P, Arunachalam G. (2017). Anticancer activity of silver and copper embedded chitin nanocomposites against human breast cancer (MCF-7) cells. Int J Biol Macromol 105:608–19. [DOI] [PubMed] [Google Scholar]
  89. Sondi I, Salopek-Sondi B. (2004). Silver nanoparticles as antimicrobial agent: a case study on E. coli as a model for Gram-negative bacteria. J Colloid Interface Sci 275:177–82. [DOI] [PubMed] [Google Scholar]
  90. Song G, Cheng L, Chao Y, et al. (2017). Emerging nanotechnology and advanced materials for cancer radiation therapy. Adv Mater 29:1700996. [DOI] [PubMed] [Google Scholar]
  91. Sriram MI, Kanth SBM, Kalishwaralal K, Gurunathan S. (2010). Antitumor activity of silver nanoparticles in Dalton’s lymphoma ascites tumor model. Int J Nanomedicine 5:753–62. [DOI] [PMC free article] [PubMed] [Google Scholar]
  92. Sung H, Ferlay J, Siegel RL, et al. (2021). Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71:209–49. [DOI] [PubMed] [Google Scholar]
  93. Thambiraj S, Shruthi S, Vijayalakshmi R, Ravi Shankaran D. (2019). Evaluation of cytotoxic activity of docetaxel loaded gold nanoparticles for lung cancer drug delivery. Cancer Treat Res Commun 21:100157. [DOI] [PubMed] [Google Scholar]
  94. Tolkaeva M, Mishra KP, Evstratova E, et al. (2021). Synergistic interaction of heavy metal salts with hyperthermia or ionizing radiation. J Radiat Cancer Res 12:23–6. [Google Scholar]
  95. Umapathi A, Navya PN, Madhyastha H, et al. (2020). Curcumin and isonicotinic acid hydrazide functionalized gold nanoparticles for selective anticancer action. Colloids Surf A Physicochem Eng Asp 607:125484. [Google Scholar]
  96. Vijayakumar TS, Mahboob S, Bupesh G, et al. (2020). Facile synthesis and biophysical characterization of egg albumen-wrapped zinc oxide nanoparticles: a potential drug delivery vehicles for anticancer therapy. J Drug Deliv Sci Technol 60:102015. [Google Scholar]
  97. Wang AZ, Langer R, Farokhzad OC. (2012). Nanoparticle delivery of cancer drugs. Annu Rev Med 63:185–98. [DOI] [PubMed] [Google Scholar]
  98. Wang Y, Chinnathambi A, Nasif O, Alharbi SA. (2021). Green synthesis and chemical characterization of a novel anti-human pancreatic cancer supplement by silver nanoparticles containing Zingiber officinale leaf aqueous extract. Arab J Chem 14:103081. [Google Scholar]
  99. Wason MS, Lu H, Yu L, et al. (2018). Cerium oxide nanoparticles sensitize pancreatic cancer to radiation therapy through oxidative activation of the JNK apoptotic pathway. Cancers 10:303. [DOI] [PMC free article] [PubMed] [Google Scholar]
  100. Wust P, Hildebrandt B, Sreenivasa G, et al. (2002). Hyperthermia in combined treatment of cancer. Lancet Oncol 3:487–97. [DOI] [PubMed] [Google Scholar]
  101. Yan L, Shen J, Wang J, et al. (2020). Nanoparticle-based drug delivery system: a patient-friendly chemotherapy for oncology. Dose Response 18:1559325820936161. [DOI] [PMC free article] [PubMed] [Google Scholar]
  102. Yu MK, Jeong YY, Park J, et al. (2008). Drug-loaded superparamagnetic iron oxide nanoparticles for combined cancer imaging and therapy in vivo. Angew Chem Int Ed Engl 47:5362–5. [DOI] [PubMed] [Google Scholar]
  103. Zeng X, Sun J, Li S, et al. (2020). Blood-triggered generation of platinum nanoparticle functions as an anti-cancer agent. Nat Commun 11:1–12. [DOI] [PMC free article] [PubMed] [Google Scholar]
  104. Zhang C, Liu Z, Zhang Y, et al. (2020). “Iron free” zinc oxide nanoparticles with ion-leaking properties disrupt intracellular ROS and iron homeostasis to induce ferroptosis. Cell Death Dis 11:183. [DOI] [PMC free article] [PubMed] [Google Scholar]
  105. Zhang Y, Li M, Gao X, et al. (2019). Nanotechnology in cancer diagnosis: progress, challenges and opportunities. J Hematol Oncol 12:1–13. [DOI] [PMC free article] [PubMed] [Google Scholar]
  106. Zhao Y, Jia R, Liu Y, et al. (2021). Specific photothermal killing of cancer cells by RNase-conjugated glyco-gold nanoparticles. Mater Today Commun 28:102640. [Google Scholar]
  107. Zhen Z, Tang W, Chen H, et al. (2013). RGD-modified apoferritin nanoparticles for efficient drug delivery to tumors. ACS Nano 7:4830–7. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Drug Delivery are provided here courtesy of Taylor & Francis

RESOURCES